RenovoRx (RNXT) Short-term Investments (2022)

RenovoRx (RNXT) posted Short-term Investments of $2.0 million for Q4 2022, down 59.19% sequentially from $5.0 million in Q3 2022.

RenovoRx (RNXT) Short-term Investments (2022) Analysis & Trends

RenovoRx has reported Short-term Investments for 1 years, with the latest figure at $2.0 million in Q4 2022.

Quarterly Short-term Investments changed N/A year-over-year to $2.0 million in Q4 2022, while the trailing twelve-month figure through Dec 2022 was $2.0 million (changed N/A YoY) and the FY2022 annual result came in at $2.0 million, changed N/A from the prior year.
Short-term Investments declined to $2.0 million in Q4 2022 per RNXT's latest filing, from $5.0 million in the prior quarter.
Over five years, Short-term Investments peaked at $8.0 million in Q2 2022 and troughed at $2.0 million in Q4 2022.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-
10	RenovoRx	62.20 Mn	62.20 Mn	766,000.00

Download Data